Trial
NCT06017297
Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Georgetown University
Collaborators
AstraZeneca
Condition
Borderline Resectable Carcinoma
Intervention
Durvalumab
Why stopped
Sponsor decision and challenges in finding eligible participants
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-12